“Against Delta variant, the vaccine Sputnik Light produces a better protection than most two-dose vaccines, “he said Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF), during his presentation at the Bloomberg Invest Global. Likewise, he advanced that the data that support his arguments about the behavior of the first component of the development of the Instituto Gamalea they will be presented next week in a study.
According to the Executive, this immunization “is more than 80% effective and can be a booster dose for other vaccines“, While highlighting the importance of” having a more direct comparison “between different sera and highlighted the performance of the Sputnik Light when combined with AstraZeneca, Modern and Sinopharm, being that these studies were carried out in the Argentina.
Furthermore, Dmitriev stated that “the goal of 800 million doses for this year will be met“And noted that” by November more than 50% of the doses of Sputnik V and Sputnik Light will be produced outside Russia. ” Moreover, to further support his sayings, he warned that “in recent weeks seven million of the second component were delivered thus complying with deliveries ”.
It is worth clarifying that the so-called Sputnik Light is actually the first component of the scheme that has two doses, being that a different adenovirus is used in each one. In this case, the S protein (spike), responsible for binding with the cell and then infecting it, which is introduced into the adenovirus called Ad26 (human adenovirus serotype 26), while the second (which has presented a greater problem in its production) is Ad5 (serotype 5 of human adenovirus).
Russia calls on institutions and scientists to evaluate the safety and efficacy of its vaccines
This Thursday, the Russian Direct Investment Fund (RDIF) announced that invite international institutions and scientists “to cooperate in real-world studies on safety and efficacy of coronavirus vaccines, including Sputnik V, Sputnik Light and others”.
As they highlighted, “the follow-up and analysis of the results of the use of the Sputnik V and Sputnik Light vaccines, as well as scientific research, are priorities for RDIF as an investor in the development and international promotion of these vaccines”, that is why they seek “Broaden the knowledge of Russian and international scientists” and promoting “public awareness of real world data.”
“RDIF actively promotes the cooperation and networking of the international scientific community on the Sputnik V vaccine. In January 2021, RDIF and the Gamaleya Center created the International Scientific Advisory Council on the Sputnik V vaccine, which brought together leading scientists in virology, microbiology, and immunology from Argentina, Great Britain, Croatia, France, Germany, India, Sweden, the United States and Russia”, They highlighted in the statement.
And, in order to support their behavior, they concluded: “Studies based on the analysis of the use of the vaccines Sputnik V and Sputnik Light have been published in the main international peer-reviewed medical journals: The Lancet, EClinical Medicine (published by The Lancet ), Vaccines, Cell Reports Medicine ”.
Disclaimer: This article is generated from the feed and not edited by our team.